Analyst Price Targets — VOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 11:58 am | — | Wedbush | $27.00 | $22.92 | TheFly | Vor Bio price target raised to $27 from $18 at Wedbush |
| May 14, 2026 12:00 pm | Martin Fan | Wedbush | $18.00 | $15.22 | TheFly | Vor Bio price target raised to $18 from $15 at Wedbush |
| April 15, 2026 10:03 am | — | H.C. Wainwright | $31.00 | $15.87 | TheFly | Vor Bio price target lowered to $31 from $32 at H.C. Wainwright |
| December 23, 2025 11:59 am | — | Robert W. Baird | $46.00 | $13.71 | TheFly | Vor Bio price target lowered to $46 from $64 at Baird |
| October 29, 2025 12:23 pm | — | H.C. Wainwright | $55.00 | $26.93 | TheFly | Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split |
| October 14, 2025 9:10 pm | — | Robert W. Baird | $64.00 | $30.81 | TheFly | Vor Bio upgraded to Outperform from Neutral at Baird |
| September 24, 2025 12:56 am | Stephen Willey | Stifel Nicolaus | $55.00 | $31.28 | TheFly | Vor Bio upgraded to Buy from Hold at Stifel |
| June 30, 2025 10:07 am | — | H.C. Wainwright | $3.00 | $1.62 | TheFly | Vor Bio upgraded to Buy from Neutral at H.C. Wainwright |
| April 27, 2022 6:14 am | — | Goldman Sachs | $6.00 | $5.60 | Benzinga | Goldman Sachs Initiates Coverage On Vor Biopharma with Neutral Rating, Announces Price Target of $6 |
Latest News for VOR
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an…
Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ: VOR) by 28,408.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 112,892 shares of the company's stock after purchasing an additional 112,496 shares during the quarter. Bank of
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th…
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease Pro-forma cash and investment balance of $514.5 million expected to provide runway into early 2029 BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage…
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 32,550 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VOR.
U.S. House Trading
No House trades found for VOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.